Computational evidence for the subitizing phenomenon as an emergent property of the human cognitive architecturePETERSON, S. A; SIMON, T. J.Cognitive science. 2000, Vol 24, Num 1, pp 93-122, issn 0364-0213Article

Effects of alendronate on gastric and duodenal mucosaLANZA, F; RACK, M. F; SIMON, T. J et al.The American journal of gastroenterology. 1998, Vol 93, Num 5, pp 753-757, issn 0002-9270Article

Effect of normalization of esophageal acid reflux time on recurrence of erosive esophagitis : randomized, placebo-controlled trial of two doses of famotidineSIMON, T. J; ROBERTS, W. G; TIPPING, R. W et al.Current therapeutic research. 1996, Vol 57, Num 1, pp 16-25, issn 0011-393XArticle

Do the magnocellular and parvocellular visual pathways contribute differentially to subitizing and counting?SIMON, T. J; PETERSON, S; PATEL, G et al.Perception & psychophysics. 1998, Vol 60, Num 3, pp 451-464, issn 0031-5117Article

Comparative tolerability profile of omeprazole in clinical trialsSIMON, T. J; BRADSTREET, D. C.Digestive diseases and sciences. 1991, Vol 36, Num 10, pp 1384-1389, issn 0163-2116Article

The dual task paradigm: speech dominance or manual dominance?SIMON, T. J; SUSSMAN, H. M.Neuropsychologia. 1987, Vol 25, Num 3, pp 559-569, issn 0028-3932Article

Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of begnign gastric ulcer : A multicenter, randomized, double-blind studyVALENZUELA, J. E; KOGUT, D. G; MCCULLOUGH, A. J et al.The American journal of gastroenterology. 1996, Vol 91, Num 12, pp 2516-2522, issn 0002-9270Article

Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitisSIMON, T. J; ROBERTS, W. G; BERLIN, R. G et al.Clinical therapeutics. 1995, Vol 17, Num 6, pp 1147-1156, issn 0149-2918Article

Chronic ethanol increases liver plasma membrane fluidityPOLOKOFF, M. A; SIMON, T. J; HARRIS, R. A et al.Biochemistry (Easton). 1985, Vol 24, Num 13, pp 3114-3120, issn 0006-2960Article

Overlapping numerical cognition impairments in children with chromosome 22q11.2 deletion or Turner syndromesSIMON, T. J; TAKARAE, Y; DEBOER, T et al.Neuropsychologia. 2008, Vol 46, Num 1, pp 82-94, issn 0028-3932, 13 p.Article

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofenLANZA, F. L; RACK, M. F; SIMON, T. J et al.Alimentary pharmacology & therapeutics. 1999, Vol 13, Num 6, pp 761-767, issn 0269-2813Article

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDsLANGMAN, M. J; JENSEN, D. M; WATSON, D. J et al.JAMA, the journal of the American Medical Association. 1999, Vol 282, Num 20, pp 1929-1933, issn 0098-7484Article

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugsTAHA, A. S; HUDSON, N; HAWKEY, C. J et al.The New England journal of medicine. 1996, Vol 334, Num 22, pp 1435-1440, issn 0028-4793, 5 p.Article

Review article : the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humansHAWKEY, C. J; JACKSON, L; HARPER, S. E et al.Alimentary pharmacology & therapeutics. 2001, Vol 15, Num 1, pp 1-9, issn 0269-2813Article

Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis : a US multi-centre double-blind studySONTAG, S. J; ROBINSON, M; DAYAL, Y et al.Alimentary pharmacology & therapeutics. 1997, Vol 11, Num 2, pp 373-380, issn 0269-2813Article

Leukotrienes in ulcerative colitis : Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591ROBERTS, W. G; SIMON, T. J; SIMON, S et al.Gastroenterology (New York, NY. 1943). 1997, Vol 112, Num 3, pp 725-732, issn 0016-5085Article

Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitisSIMON, T. J; BERENSON, M. M; BERLIN, R. G et al.Alimentary pharmacology & therapeutics. 1994, Vol 8, Num 1, pp 71-79, issn 0269-2813Article

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitisSIMON, T. J; BERLIN, R. G; TIPPING, R et al.Scandinavian journal of gastroenterology. 1993, Vol 28, Num 5, pp 375-380, issn 0036-5521Article